ArticleBMC cancer2014
Cancer risks among patients with type 2 diabetes: a 10-year follow-up study of a nationwide population-based cohort in Taiwan.
Article in BMC cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 5 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Meta-analysis of the Relationship between Type 2 Diabetes Mellitus and Renal Cancer Risk.Endocrine, metabolic & immune disorders drug targets · 2024Pooled it
- The relationship between metabolic syndrome and its components with bladder cancer: a systematic review and meta-analysis of cohort studies.Epidemiology and health · 2022Pooled it
- Pooled it
- Diabetes mellitus and the risk of gastrointestinal cancer in women compared with men: a meta-analysis of cohort studies.BMC cancer · 2018Pooled it
- A Powerful Procedure for Pathway-Based Meta-analysis Using Summary Statistics Identifies 43 Pathways Associated with Type II Diabetes in European Populations.PLoS genetics · 2016Pooled it
- New-Onset Type 2 Diabetes Mellitus and Cancer Risk: A Matched Cohort Study in China Kadoorie Biobank.International journal of cancer · 2026Article
- Body mass index and risk of connective and soft tissue cancer: results from a large cohort of 1.7 million individuals in Norway.BMC cancer · 2025Article
- Body mass index and penile cancer incidence: results from a Norwegian cohort study of 829,081 men.BMC urology · 2024Article
- Associations between depression and cancer risk among patients with diabetes mellitus: A population-based cohort study.Cancer medicine · 2023Article
- Cancer and diabetes co-occurrence: A national study with 44 million person-years of follow-up.PloS one · 2022Article
- Older veterans associated with reduced risk of cancer: Retrospective nationwide matched cohort study in Taiwan.Frontiers in medicine · 2022Article
- Article
- History of Diabetes Mellitus and Risk of Breast Cancer in Asian Women: A Meta-Epidemiological Analysis of Population-Based Cohort Studies.Journal of menopausal medicine · 2020Article
- Increased risk of tuberculosis in oral cancer patients in an endemic area: a nationwide population-based study.Clinical oral investigations · 2019Article
- The long-term rapid increase in incidence of adenocarcinoma of the kidney in the USA, especially among younger ages.International journal of epidemiology · 2019Article
- Geographic distribution and time trends of esophageal cancer in Brazil from 2005 to 2015.Molecular and clinical oncology · 2019Article
- Prediabetes and diabetes in relation to risk of gastric adenocarcinoma.British journal of cancer · 2019Article
- Traditional Chinese medicine use is associated with lower end-stage renal disease and mortality rates among patients with diabetic nephropathy: a population-based cohort study.BMC complementary and alternative medicine · 2019Article
- High Glucose with Insulin Induces Cell Cycle Progression and Activation of Oncogenic Signaling of Bladder Epithelial Cells Cotreated with Metformin and Pioglitazone.Journal of diabetes research · 2019Article
- Body mass index and cancer risk among Chinese patients with type 2 diabetes mellitus.BMC cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to determine cancer risks among patients with type 2 diabetes through a follow-up study on a nationwide population-based cohort that included Taiwanese diabetic patients and general population in Taiwan as well as to estimate the population attributable fraction (PAF) of site-specific cancer risks that can be attributed to type 2 diabetes in Taiwanese population by using standardized incidence ratios (SIRs, 95% CI).
methodsSubjects with type 2 diabetes consisted of 472,979 patients aged ≥ 20 years, whereas general population consisted of 9,411,249 individuals of the same age limit but are not diabetic. Subjects were identified from 1997 to 1998 and followed up until December 31, 2007 or until the first manifestation of any cancer.
resultsCancer sites with increased risks in men, which were consistent with the main and sensitivity analyses, included pancreas (SIR=1.62; 95% CI=1.53 to 1.72), liver (1.61; 1.57 to 1.64), kidney (1.32; 1.25 to 1.40), oral (1.16, 1.12 to 1.21), and colorectal (1.19, 1.15 to 1.22). Cancer sites with increased risks in women included liver (1.55; 1.51 to 1.60), pancreas (1.44; 1.34 to 1.55), kidney (1.38; 1.30 to 1.46), endometrium (1.36; 1.26 to 1.47), bladder (1.19; 1.11 to 1.27), colorectal (1.16; 1.13 to 1.20), and breast (1.14; 1.09 to 1.18). Overall, PAFs were highest for liver cancer in men (4.0%) and women (3.7%), followed by pancreas (3.4%) and kidney (1.6%) cancers in men, and then for endometrium (1.8%) and kidney (1.8%) cancers in women.
conclusionOur data suggested that increased cancer risks are associated with type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.